Blockade of myeloid-derived suppressor cells after induction of lymphopenia improves adoptive T cell therapy in a murine model of melanoma. - Wikidata - awgldk - TriplyDB

Blockade of myeloid-derived suppressor cells after induction of lymphopenia improves adoptive T cell therapy in a murine model of melanoma.

Blockade of myeloid-derived suppressor cells after induction of lymphopenia improves adoptive T cell therapy in a murine model of melanoma.

http://www.wikidata.org/entity/Q36422292

about

TCR-Engineered T Cells Meet New Challenges to Treat Solid Tumors: Choice of Antigen, T Cell Fitness, and Sensitization of Tumor Milieu Trial Watch: Adoptive cell transfer for oncological indications Relevance of tumor-infiltrating lymphocytes in breast cancer Hampering immune suppressors: therapeutic targeting of myeloid-derived suppressor cells in cancer Pathways and therapeutic targets in melanoma Improving cancer immunotherapy by targeting the STATe of MDSCs Harnessing the Microbiome to Enhance Cancer Immunotherapy Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein.Immunosuppressive myeloid cells induced by chemotherapy attenuate antitumor CD4+ T-cell responses through the PD-1-PD-L1 axis Myeloid-derived suppressor cells are associated with disease progression and decreased overall survival in advanced-stage melanoma patients Manipulation of Innate and Adaptive Immunity through Cancer Vaccines.The calcineurin-NFAT axis controls allograft immunity in myeloid-derived suppressor cells through reprogramming T cell differentiation Intralesional injection of rose bengal induces a systemic tumor-specific immune response in murine models of melanoma and breast cancer Elimination of metastatic melanoma using gold nanoshell-enabled photothermal therapy and adoptive T cell transfer Novel role of hematopoietic stem cells in immunologic rejection of malignant gliomas.Modulation of Acid Sphingomyelinase in Melanoma Reprogrammes the Tumour Immune Microenvironment 6-Thioguanine-loaded polymeric micelles deplete myeloid-derived suppressor cells and enhance the efficacy of T cell immunotherapy in tumor-bearing mice.Impact of a New Fusion Receptor on PD-1-Mediated Immunosuppression in Adoptive T Cell Therapy Myeloid derived suppressor cells: Targets for therapy.Dendritic cell immunotherapy combined with gemcitabine chemotherapy enhances survival in a murine model of pancreatic carcinoma Trial Watch: Adoptive cell transfer for anticancer immunotherapy.Therapeutic targeting of myeloid-derived suppressor cells involves a novel mechanism mediated by clusterin.Deficiency of Kruppel-like factor KLF4 in mammary tumor cells inhibits tumor growth and pulmonary metastasis and is accompanied by compromised recruitment of myeloid-derived suppressor cells Current adoptive immunotherapy in non-small cell lung cancer and potential influence of therapy outcome.Chronic inflammation and cancer: suppressing the suppressors.Breaking immunotolerance of tumors: a new perspective for dendritic cell therapy.A new hope in immunotherapy for malignant gliomas: adoptive T cell transfer therapy.Enhancing the efficacy of adoptive cellular therapy by targeting tumor-induced immunosuppression.Myeloid-derived suppressor cell function is reduced by Withaferin A, a potent and abundant component of Withania somnifera root extract.Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy.Chemotherapy-induced myeloid suppressor cells and antitumor immunity: The Janus face of chemotherapy in immunomodulation.Contrasting effects of cyclophosphamide on anti-CTL-associated protein 4 blockade therapy in two mouse tumor models.Newly Characterized Murine Undifferentiated Sarcoma Models Sensitive to Virotherapy with Oncolytic HSV-1 M002.Trial Watch: Adoptive cell transfer for anticancer immunotherapy.Nitric oxide mediated inhibition of antigen presentation from DCs to CD4+ T cells in cancer and measurement of STAT1 nitration.Targeting Myeloid-Derived Suppressor Cells in Cancer.Tissue-Dependent Tumor Microenvironments and Their Impact on Immunotherapy Responses.Trial Watch: Adoptively transferred cells for anticancer immunotherapy.The Pharmacology of T Cell Therapies.Genetics and biology of prostate cancer

P2860

Q21131200-45E8A74F-77BD-4F72-BA46-3C0B96EBA192 Q26785545-8FD94136-F26D-43E8-B2CD-9C5D51C5A362 Q26795598-857068D5-E605-49B9-A72D-EA8C3A47850E Q26863418-079A5617-E1F4-4F4A-BDC4-4834D4FEE32B Q26865736-F12578D4-8B19-4E66-8E26-3D803B80F63A Q28066797-5D8D04FF-1B62-4FE9-B79C-89A894A60202 Q28088598-16A86D08-9695-47DB-808A-A806E5D4424E Q33781150-87AF3A07-01A3-42CF-A7D0-21354DDC18A6 Q33838944-D3D07CA1-2373-433E-93DF-558AAB42CC27 Q34250873-BD81DB77-9B55-4AF7-A152-AC3CD05ADA85 Q34552791-7827B413-DB8F-4C15-880C-CC33906F71FA Q34846497-791C61A0-D3E8-403C-A99D-7DFFCDC56AEE Q34849409-F0C0190A-978D-4864-86E5-32FF9BCD8E5B Q34919077-EB54CC9F-877A-4196-8CEC-8180EE28D0DF Q35507524-78EDF253-F1A0-4E11-B060-751889992C2F Q35697896-BEAFE6DD-0A74-4CC2-A543-DF681B922415 Q35863346-0ED785FD-2EA5-4770-B0A5-2C35474ED8D9 Q36173500-1EF5106A-E57E-41B2-B250-09CFC05AB02F Q36845851-ECFE8356-A358-4BFA-A7E2-5F2DA743A20A Q36883666-1BA92298-804F-4476-B217-0B284BCCFC3F Q36887833-43FECCF2-F0B3-4C66-B6EB-D78E2047DD53 Q37089543-09D65E9B-C0ED-4760-B980-45B3A07B34B1 Q37228480-084C4D3E-444E-4BE4-8D7C-A2ADE8E4C637 Q38088013-82E3B050-96D7-47C8-BF5C-01380DE591D7 Q38132688-02753C3E-6146-49C7-80D0-788049BE3567 Q38185156-8BFD8B24-B00D-4871-AE2E-11C426F6A7C2 Q38227889-81498280-67D5-41DF-99A6-5C5D46567FC8 Q38525024-2EEEB3F7-E80D-4894-B34F-D010CA3102A1 Q39104155-B173F9A0-5121-4500-9FD4-ECBB81AFAC59 Q39130451-C9783212-63D9-42F1-8490-C3698F6A8DFD Q42177586-0FE1BD7A-3391-4E44-9389-8322D17BBDF9 Q42288675-77652C5C-C713-4C43-AC72-61477B6CFA06 Q42373511-70652E16-00D8-4010-BF7F-D37D8E210EDA Q42702234-6D2A00C7-4210-479A-B37B-B8F0EABBE58D Q47144801-87E402C9-538A-4CAA-8779-BCF09BEBBD44 Q47765346-CBA820A8-6D08-43B9-83C9-B4F379FC3A28 Q49694802-07E586BC-1BC1-4CC9-A043-2B8F49170A2C Q52780137-BA5CB770-2EA5-4BAA-84D1-E2A62A0E6408 Q54985631-DC6FD644-4982-4388-A445-58C0D9D4794E Q57106917-101E8BB8-3EA9-478F-B5A2-1B4623ACD10A

P2860

Blockade of myeloid-derived suppressor cells after induction of lymphopenia improves adoptive T cell therapy in a murine model of melanoma.

http://www.wikidata.org/entity/Q36422292

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh

2012年學術文章

@zh-hant

name

Blockade of myeloid-derived su ...... in a murine model of melanoma.

@ast

Blockade of myeloid-derived su ...... in a murine model of melanoma.

@en

type

label

Blockade of myeloid-derived su ...... in a murine model of melanoma.

@ast

Blockade of myeloid-derived su ...... in a murine model of melanoma.

@en

prefLabel

Blockade of myeloid-derived su ...... in a murine model of melanoma.

@ast

Blockade of myeloid-derived su ...... in a murine model of melanoma.

@en

P1433

Q36422292-61E12B60-8F5B-4367-B2A3-CE7B6E1EF8E1

P1476

Q36422292-537952EB-0664-4A33-8AE7-60D3CFB2166B

P2093

Q36422292-33CABC5A-D2BB-4A50-AE61-26CE8F475F81

Q36422292-45D4B8C7-8F43-4A9D-AE18-BDEBCAC0115E

Q36422292-8844E0EF-62EC-47B6-8A1E-F993DBEC32F5

Q36422292-8BEDB011-3D30-4D25-8498-988B782CFFE2

P2860

Q36422292-015BEAED-B15D-4C15-8F2E-61608021C641

Q36422292-0B352835-9CF9-48D2-8630-C922E422D68D

Q36422292-0D8201AF-19EA-4EAB-8E56-FF41EF199878

Q36422292-12901594-8ECB-4F28-9029-1D23D9AB946B

Q36422292-13B0E77D-B9A7-4692-A584-086B4D824644

Q36422292-185E5ECF-F9E3-4BB8-9967-72BEE5344AA6

Q36422292-20101A21-58BB-45F9-971C-F0B5E6ED2C11

Q36422292-25759862-8957-4200-9C0C-A3884C764687

Q36422292-2B0E1113-8A93-4992-BC01-47EDF36B7DD6

Q36422292-2F696380-EA73-4A6C-8259-9719599E7841

P304

Q36422292-731C3360-0828-4A60-9053-3E3C2C009C2F

P31

Q36422292-A099AD48-DC66-45F1-BC27-AD39167B9137

P356

Q36422292-87F4F82A-4B0B-4C7D-AB6D-A73447263411

P407

Q36422292-1D464282-A8E8-4A4D-B579-E096DDB1B481

P433

Q36422292-3FBED238-77B9-4A07-B895-C0A78868A96E

P478

Q36422292-DB8B7CF6-17AA-4ED0-BE22-FE686F2DFD06

P577

Q36422292-614E6530-C9C0-4A10-874C-2D516880CD6E

P698

Q36422292-F801CC2E-564A-4CD7-B865-47CF23712600

P932

Q36422292-94FDFBE3-C707-4B35-AD30-8872F3559A0B

P356

JIMMUNOL.1200274

P1433

Journal of Immunology

P1476

Blockade of myeloid-derived su ...... in a murine model of melanoma.

@en

P2093

Amod A Sarnaik

http://www.w3.org/2001/XMLSchema#string

Amy Weber

http://www.w3.org/2001/XMLSchema#string

Krithika N Kodumudi

http://www.w3.org/2001/XMLSchema#string

Shari Pilon-Thomas

http://www.w3.org/2001/XMLSchema#string

P2860

Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells

Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma

Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens

Coordinated regulation of myeloid cells by tumours

Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function

Macrophage-derived nitric oxide regulates T cell activation via reversible disruption of the Jak3/STAT5 signaling pathway

Cancer statistics, 2009

Regulation of immune responses by L-arginine metabolism

Subsets of myeloid-derived suppressor cells in tumor-bearing mice

A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma

P304

5147-5154

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4049/JIMMUNOL.1200274

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

189

http://www.w3.org/2001/XMLSchema#string

P577

2012-10-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23100512

http://www.w3.org/2001/XMLSchema#string

P932

3505990

http://www.w3.org/2001/XMLSchema#string